Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M, Redondo A, Heredia-Soto V, Herranz J, Berjón A, Hernández A, Miguel-Martín M, Crespo R, Barriuso J, Cruz P, Yébenes L, Peláez-García A, Castelo B, DE Molina AR, Feliu J, Hardisson D. Mendiola M, et al. Among authors: berjon a. Anticancer Res. 2018 Sep;38(9):5393-5400. doi: 10.21873/anticanres.12869. Anticancer Res. 2018. PMID: 30194194
Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer.
Mendiola M, Pellinen T, Ramon-Patino JL, Berjon A, Bruck O, Heredia-Soto V, Turkki R, Escudero J, Hemmes A, Garcia de la Calle LE, Crespo R, Gallego A, Hernandez A, Feliu J, Redondo A. Mendiola M, et al. Among authors: berjon a. Mod Pathol. 2022 Feb;35(2):256-265. doi: 10.1038/s41379-021-00930-7. Epub 2021 Oct 12. Mod Pathol. 2022. PMID: 34642425 Free article.
Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?
Escudero J, Heredia-Soto V, Wang Y, Ruiz P, Hu Y, Gallego A, Pozo-Kreilinger JJ, Martinez-Marin V, Berjon A, Ortiz-Cruz E, Bernabeu D, Feliu J, Tang J, Redondo A, Mendiola M. Escudero J, et al. Among authors: berjon a. Cancer Cell Int. 2021 Dec 4;21(1):646. doi: 10.1186/s12935-021-02337-5. Cancer Cell Int. 2021. PMID: 34863177 Free PMC article.
Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models.
Heredia-Soto V, Escudero J, Miguel M, Ruiz P, Gallego A, Berjón A, Hernández A, Martínez-Díez M, Zheng S, Tang J, Hardisson D, Feliu J, Redondo A, Mendiola M. Heredia-Soto V, et al. Among authors: berjon a. Front Oncol. 2022 Mar 17;12:862321. doi: 10.3389/fonc.2022.862321. eCollection 2022. Front Oncol. 2022. PMID: 35372006 Free PMC article.
Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer.
Gallego A, Mendiola M, Hernando B, Berjon A, Cadiz A, Chaves-Urbano B, Heredia-Soto V, Spagnolo E, Hernández Gutiérrez A, Hardisson D, Macintyre G, Redondo A, Garcia MJ. Gallego A, et al. Among authors: berjon a. Int J Gynecol Cancer. 2022 Aug 1;32(8):1009-1016. doi: 10.1136/ijgc-2022-003353. Int J Gynecol Cancer. 2022. PMID: 35437272
Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.
Peláez-García A, Yébenes L, Berjón A, Angulo A, Zamora P, Sánchez-Méndez JI, Espinosa E, Redondo A, Heredia-Soto V, Mendiola M, Feliú J, Hardisson D. Peláez-García A, et al. Among authors: berjon a. PLoS One. 2017 Sep 8;12(9):e0183452. doi: 10.1371/journal.pone.0183452. eCollection 2017. PLoS One. 2017. PMID: 28886093 Free PMC article.
41 results